VUH PGY1 Pharmacy Residency Program
Residency Purpose Statement
The Vanderbilt University Hospital (VUH) PGY1 residency programs build upon Doctor of Pharmacy (PharmD) education and outcomes to develop pharmacist practitioners with knowledge, skills, and abilities as defined in the educational competency areas, goals, and objectives. Residents who successfully complete PGY1 residency programs will be skilled in diverse patient care, practice management, leadership, and education, and be prepared to provide patient care, seek board certification in pharmacotherapy (i.e., BCPS), and pursue advanced education and training opportunities including postgraduate year two (PGY2) residencies.
Program Overview
The Vanderbilt University Hospital (VUH) PGY-1 Pharmacy Residency is a 12-month program accredited by the American Society of Health-System Pharmacists, and was initiated in 1993 with one residency position. It has grown over the years to five positions. This residency offers the opportunity to learn and practice pharmaceutical care in an acute inpatient setting. Experiences are offered in management, critical care, cardiology, oncology, nutrition, transplant, pediatrics, general medicine, and informatics. One focus of our program is to customize the PGY1 learning experience to the resident. This is accomplished by having multiple elective rotations and tailoring the program to each residents’ individual goals.
Rotations
All clinical rotations are approximately 4 weeks duration and correspond with the calendar month.
| Required | Elective | |
| Internal Medicine | Emergency Medicine | Infectious Disease - Rogers ID |
| Administration | General Pediatrics | Neonatal ICU |
| Pharmacy Orientation | Endocrinology Outpatient Clinic | Pediatric Cardiac ICU |
| HIV Ambulatory Care | Pediatric Oncology and Stem Cell Transplant | |
| Selective (two required) | Infectious Diseases 1 | Pulmonary Medicine |
| Trauma ICU | Informatics | Stem Cell Transplant & Cellular Therapy |
| Surgical ICU | Mechanical Cardiac Support | Stroke/Neurology |
| Medical ICU | Pediatric ICU | Heart/Lung Transplant |
| Neuro ICU | Malignant Hematology | Kidney/Pancreas Transplant |
| ICU Nutrition Support | Medical Oncology | Liver Transplant |
| Cardiology Critical Care | Medical Outpatient Oncology - GI Clinic | Vanderbilt Familiar Faces |
| Medical Outpatient Oncology - Thoracic Clinic | Cardiology |
Longitudinal Experiences
| Required Longitudinal Experiences |
| Hospital Pharmacy Practice Staffing |
| Code Response |
| Journal Club x 2 |
| Therapeutic Exchange |
| Medication Use Evaluation |
| Drug Monograph |
| Research Project |
| Presentation of Research Project at the Regional Residency Conference |
| Coordination of InPharmation |
| Case Presentation x 2 |
| Optional Longitudinal Experiences |
| Teaching Certificate |
| Click here for more information on longitudinal experiences |
Selected Resident Publications
Safety of an Accelerated Ferric Gluconate Inpatient Infusion Regimen
Gray E, Parrot T, McCluggage L.
Journal of Pharmacy Technology. 2024 Oct 27. Epub ahead of print
Evaluating antibiotic de-escalation for autologous stem cell transplant patients with febrile neutropenia in a real-world clinical setting.
Winget M, Gatwood K, Jayani R, et al.
Transplant Cell Ther. 2024 Oct;30(10):1031.
Tapering opioids in patients with persistent pain after cancer treatment.
Butler TW, Lochridge BM, Hande K, et. al.
Pain Medicine, 2024 Jul 16:pnae061.
Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influence on tacrolimus dose adjusted concentrations in adult heart transplant recipients.
Liu M, Hernandez S, Aquilante CL, et al.
Pharmacogenomics J. 2024 Feb 15;24(2):4.
Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal.
Peterson ME, Jaynes MP, Berardi S, Morton C.
J Thromb Thrombolysis. 2024 Jun;57(5):865-870.
Conversion between sirolimus and everolimus in heart transplant recipients.
Wert T, Heeney S, Morrison M.
Clin Transplant. 2023 Nov;37(11):e15102.
Quantifying Critical Care Pharmacist Interventions in COVID-19.
Pluenneke JC, Semler MW, Casey JD, et al.
Journal of Intensive Care Medicine Feb 2023
Identifying Predictors of Extubation on the day of Passing an SBT in Critically ill Adults.
Patel S, Stollings JL, Casey JD, et al.
J Intensive Care Med. 2023 Jun; 38(6):529-533.
5 verus 10 Units of Intravenous Insulin for Hyperkalemia in Patients with Moderate Renal Dysfunction.
Finder SN, McLaughlin LB, Dillon RC.
J Emerg Med. 2022 Mar;62(3):298-305.
Evaluation of healthcare-associated infection rates in patients with hematologic malignancies and stem cell transplantation during the coronavirus disease 2019 (COVID-19) pandemic.
Bobbitt LJ, Satyanarayana G, Van Metre Baum L, Nebhan CA, Kassim AA, Gatwood KS
Antimicrobial Stewardship & Healthcare Epidemiology 2022:2(1):e11
The Efficacy and Safety of Methylnaltrexone for the Treatment of Postoperative Ileus. Am Surg
Beavers J, Orton L, Atchison A, et al.
2021 Oct 13. 31348211048825. doi: 10.1177/00031348211048825. Online ahead of print.
New-onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide
Mangan BL, Patel D, Chen H, Gatwood K, et al.
eJHaem 2020;1-5
Driving antimicrobial use improvement: attitudes of providers of adult hospital care on optimal attribution and feedback
Lines, TH, Nesbitt WJ, Nelson GE
Infection Control and Hospital Epidemiology 2018;39(8) : 983-985
Time to First Culture Positivity Among Critically Ill Adults with Methicillin-Resistant Staphylococcus aureus Growth in Respiratory or Blood Cultures
Melling PA, Noto MJ, Rice TW, et al.
Annals of Pharmacotherapy 2019 Sept 22
International Analgesia, Sedation, and Delirium Practices: a prospective cohort study
Owen GD, Stollings JL, Rakhit S, et al.
Journal of Intensive Care 2019;7(25):3-7
Antimicrobial Exposure and the Risk of Delirium in Critically Ill Patients
Grahl JJ, Stollings JL, Rakhit S, Person AK, et al.
Critical Care 2018;22:337
Defining Incidence and Risk Factors for Catheter-Associated Bloodstream Infections in an Outpatient Adult Hematopoietic Cell Transplantation Program
McDonald MK, Culos KA, Gatwood KS, et al.
Biol Blood Marrow Transplant. 2018 (00);1-7
“Real-World” Application of Thrombolysis in Cardiac Arrest
Smith SE, Johnson DC.
J Pharm Pract. 2018 Sep 13
Click here to see more resident publications
Program Details
|
Application Information
Number of Positions: Five
Residency starting date: June 16, 2025
Paid Time Off (PTO) including holidays: 16 days
Estimated stipend - approx. $60,000
Application Requirements
Doctor of Pharmacy degree from an ACPE accredited degree program, CV, letter of intent, three letters of recommendation (minimum of two letters from clinical preceptors), transcripts for pharmacy coursework, licensure in Tennessee, and GPA greater than 3.25. Candidates from pass/fail pharmacy schools will be given full consideration.
The VUH pharmacy residency program is NOT able to sponsor visas for pharmacy residents.
Submit application in PhORCAS application portal by January 2 deadline
Contact Information
email: pgy1pharmresidency@vumc.org
Kelli Rumbaugh, PharmD, BCCCP, FCCM PGY1 Residency Program Director
Vanderbilt University Medical Center Department of Pharmacy
1211 Medical Center Drive B131 VUH Nashville, TN 37232-7610
Institutional Information
Private non-profit hospital/clinic teaching/tertiary model | Total Beds = 1741
Professional Staff = 450 | Non-professional staff = 586